PLXPQ — PLx Pharma Winddown Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- -$9.82m
- $8.21m
- 18
- 83
- 11
- 30
Annual income statement for PLx Pharma Winddown, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.779 | 0.753 | 0.565 | 0.03 | 8.21 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 3.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.6 | 11.7 | 14.8 | 13.5 | 49 |
| Operating Profit | -15.8 | -11 | -14.2 | -13.5 | -40.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -16.3 | 0.896 | -20.5 | -15.2 | -46.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -15.3 | 0.896 | -20.5 | -15.2 | -46.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15.3 | 0.896 | -20.5 | -15.2 | -46.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.3 | 0.896 | -34.3 | -16.9 | -48.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.97 | 0.103 | -3.84 | -1.74 | -2.06 |